Monomethyl Fumarate
Generic Name: monomethyl fumarate
Brand Names:
Bafiertam
11 DESCRIPTION BAFIERTAM contains the active ingredient monomethyl fumarate, which is an unsaturated monomethyl ester. It is also known by its chemical name, fumaric acid monomethyl ester, (C 5 H 6 O 4 ). It has the following structure: Monomethyl fumarate is a white to off-white powder that is highly soluble in water with a molecular mass of 130.10.
Overview
11 DESCRIPTION BAFIERTAM contains the active ingredient monomethyl fumarate, which is an unsaturated monomethyl ester. It is also known by its chemical name, fumaric acid monomethyl ester, (C 5 H 6 O 4 ). It has the following structure: Monomethyl fumarate is a white to off-white powder that is highly soluble in water with a molecular mass of 130.10.
Uses
1 INDICATIONS AND USAGE BAFIERTAM is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BAFIERTAM is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )
Dosage
2 DOSAGE AND ADMINISTRATION Blood tests are required prior to initiation of BAFIERTAM. ( 2.1 ) Starting dose: 95 mg twice a day, orally, for 7 days ( 2.2 ) Maintenance dose after 7 days: 190 mg (administered as two 95 mg capsules) twice a day, orally ( 2.2 ) Swallow BAFIERTAM capsules whole and intact. Do not crush, chew, or mix contents with food. ( 2.3 ) Take BAFIERTAM with or without food. ( 2.3 ) 2.1 Blood Tests Prior to Initiation of BAFIERTAM Obtain the following prior to treatment with BAFIERTAM: A complete blood cell count (CBC), including lymphocyte count [see Warnings and Precautions ( 5.4 )] . Serum aminotransferase, alkaline phosphatase, and total bilirubin levels [see Warnings and Precautions ( 5.5 )] .
Side Effects
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Anaphylaxis and Angioedema [see Warnings and Precautions ( 5.1 )] Progressive Multifocal Leukoencephalopathy [see Warnings and Precautions ( 5.2 ) ] Herpes Zoster and Other Serious Opportunistic Infections [see Warnings and Precautions ( 5.3 ) ] Lymphopenia [see Warnings and Precautions ( 5.4 )] Liver Injury [see Warnings and Precautions ( 5.5 )] Flushing [see Warnings and Precautions ( 5.6 )] Serious Gastrointestinal Reactions [see Warnings and Precautions ( 5.7 )] Most common adverse reactions (incidence for dimethyl fumarate [the prodrug of BAFIERTAM] ≥10% and ≥2% more than placebo) were flushing, abdominal pain, diarrhea, and nausea.
Interactions
7 DRUG INTERACTIONS 7.1 Concomitant Dimethyl Fumarate or Diroximel Fumarates Both dimethyl fumarate and diroximel fumarate are metabolized to monomethyl fumarate. Therefore, BAFIERTAM is contraindicated in patients currently taking dimethyl fumarate or diroximel fumarate. BAFIERTAM may be initiated the day following discontinuation of either of these drugs.
Warnings
5 WARNINGS AND PRECAUTIONS Anaphylaxis and Angioedema: Discontinue and do not restart BAFIERTAM if these occur. ( 5.1 ) Progressive Multifocal Leukoencephalopathy (PML): Withhold BAFIERTAM at the first sign or symptom suggestive of PML. ( 5.2 ) Herpes Zoster and Other Serious Opportunistic Infections: Consider withholding BAFIERTAM in cases of serious infection until the infection has resolved. ( 5.3 ) Lymphopenia: Obtain a CBC including lymphocyte count before initiating BAFIERTAM, after 6 months, and every 6 to 12 months thereafter. Consider interruption of BAFIERTAM if lymphocyte counts <0.5 x 10 9 /L persist for more than six months. 4 CONTRAINDICATIONS BAFIERTAM is contraindicated in patients: with known hypersensitivity to monomethyl fumarate, dimethyl fumarate, diroximel fumarate, or to any of the excipients of BAFIERTAM. Reactions may include anaphylaxis or angioedema [see Warnings and Precautions ( 5.1 )]. taking dimethyl fumarate or diroximel fumarate [see Drug Interactions ( 7.1 )].
Pregnancy
8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to BAFIERTAM during pregnancy. Pregnant women exposed to BAFIERTAM and healthcare providers are encouraged to contact Banner Life Sciences at 1-866-MMF-95MG (1-866-663-9564). Risk Summary There are no adequate data on the developmental risk associated with the use of BAFIERTAM in pregnant women.
Storage
16.2 Storage and Handling Unopened Bottle Store unopened bottles in refrigerator at 2°C to 8°C (35°F to 46°F). Do not freeze. Under these conditions, BAFIERTAM is stable until the expiration date indicated on the package. Opened Bottle Opened bottles may be stored at 20°C to 25°C (68°F to 77°F); excursions between 15°C and 30°C (59°F and 86°F) permitted [see USP Controlled Room Temperature].
Frequently Asked Questions
What is Monomethyl Fumarate used for?▼
1 INDICATIONS AND USAGE BAFIERTAM is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BAFIERTAM is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )
What are the side effects of Monomethyl Fumarate?▼
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Anaphylaxis and Angioedema [see Warnings and Precautions ( 5.1 )] Progressive Multifocal Leukoencephalopathy [see Warnings and Precautions ( 5.2 ) ] Herpes Zoster and Other Serious Opportunistic Infections [see Warnings and Precautions ( 5.3 ) ] Lymphopenia [see Warnings and Precautions ( 5.4 )] Liver Injury [see Warnings and Precautions ( 5.5 )] Flushing [see Warnings and Precautions ( 5.6 )] Serious Gastrointestinal Reactions [see Warnings and Precautions ( 5.7 )] Most common adverse reactions (incidence for dimethyl fumarate [the prodrug of BAFIERTAM] ≥10% and ≥2% more than placebo) were flushing, abdominal pain, diarrhea, and nausea.
Can I take Monomethyl Fumarate during pregnancy?▼
8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to BAFIERTAM during pregnancy. Pregnant women exposed to BAFIERTAM and healthcare providers are encouraged to contact Banner Life Sciences at 1-866-MMF-95MG (1-866-663-9564). Risk Summary There are no adequate data on the developmental risk associated with the use of BAFIERTAM in pregnant women.
What are the important warnings for Monomethyl Fumarate?▼
5 WARNINGS AND PRECAUTIONS Anaphylaxis and Angioedema: Discontinue and do not restart BAFIERTAM if these occur. ( 5.1 ) Progressive Multifocal Leukoencephalopathy (PML): Withhold BAFIERTAM at the first sign or symptom suggestive of PML. ( 5.2 ) Herpes Zoster and Other Serious Opportunistic Infections: Consider withholding BAFIERTAM in cases of serious infection until the infection has resolved. ( 5.3 ) Lymphopenia: Obtain a CBC including lymphocyte count before initiating BAFIERTAM, after 6 months, and every 6 to 12 months thereafter. Consider interruption of BAFIERTAM if lymphocyte counts <0.5 x 10 9 /L persist for more than six months. 4 CONTRAINDICATIONS BAFIERTAM is contraindicated in patients: with known hypersensitivity to monomethyl fumarate, dimethyl fumarate, diroximel fumarate, or to any of the excipients of BAFIERTAM. Reactions may include anaphylaxis or angioedema [see Warnings and Precautions ( 5.1 )]. taking dimethyl fumarate or diroximel fumarate [see Drug Interactions ( 7.1 )].
Related Medications
Amlexanox
amlexanox
Dosage form: POWDER. Active ingredients: AMLEXANOX (100 g/100g). Category: BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING.
Acetaminophen And Dextromethorphan Hydrobromide
acetaminophen and dextromethorphan hydrobromide
Active ingredients (in each 20 mL) Purposes Acetaminophen 650 mg Pain reliever/fever reducer Dextromethorphan HBr 20 mg Cough suppressant
Antimonium Crudum, Arsenicum Album, Bismuthum Subnitricum, Borax, Bryonia (alba), Calcarea Phosphorica, Candida Albicans, Chamomilla, Cinchona Officinalis, Discus Intervertebralis Suis, Streptococcus Dysgalactiae Dna, Streptococcus Mutans Dna, Streptococcus Pneumoniae Dna, Echinacea Purpurea, Ignatia Amara, Juglans Cinerea, Kali Muriaticum, Magnesia Muriatica, Mercurius Solubilis, Muriaticum Acidum, Nux Moschata, Oral Mucosa (suis), Oxygenium, Sambucus Nigra, Sepia, Staphylococcus Aureus,
antimonium crudum, arsenicum album, bismuthum subnitricum, borax, bryonia (alba), calcarea phosphorica, candida albicans, chamomilla, cinchona officinalis, discus intervertebralis suis, streptococcus dysgalactiae dna, streptococcus mutans dna, streptococcus pneumoniae dna, echinacea purpurea, ignatia amara, juglans cinerea, kali muriaticum, magnesia muriatica, mercurius solubilis, muriaticum acidum, nux moschata, oral mucosa (suis), oxygenium, sambucus nigra, sepia, staphylococcus aureus,
Non-Standardized Fungal Allergenic Extract [EPC]
PURPOSE: Antimonium Crudum – Mouth Support, Arsenicum Album – Dental Support, Bismuthum Subnitricum – Pain in Ears, Borax – Dry Mouth, Bryonia (Alba) – Eruption on Tongue, Calcarea Phosphorica – Dental Issues, Candida Albicans – Eruption on Cheeks, Chamomilla – Teeth Sensitivity, Cinchona Officinalis – Mouth Support, Discus Intervertebralis Suis – Dry Mouth, DNA – Mouth Support, Echinacea Purpurea – Mouth Support, Ignatia Amara – Teeth Sensitivity, Juglans Cinerea – Pain in Ears, Kali Muriaticum
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.